Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback ...
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ˜HOOKIPA™), a company developing a new class of immunotherapeutics based on its proprietary...
NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ˜HOOKIPA™), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK...
Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2...
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
HOOKIPA Pharma Provides Update on Business Priorities
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA™s outstanding...
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen for human immunodeficiency virus (HIV)Phase 1...